Vicore Pharma is granted orphan drug designation for C21 for the treatment of IPF

The European Commission has granted orphan drug status for Vicore Pharma’s lead compound C21 for the treatment of idiopathic pulmonary fibrosis (IPF). 

The European Commission has adopted the opinion issued by EMA to grant orphan drug status for C21, the lead compound developed by Vicore Pharma, for the treatment of IPF. The approval follows on a positive opinion by the EMA where the authority was particularly impressed with the preclinical effects on the pulmonary hypertension aspects of the disease as demonstrated in models of monocrotaline and bleomycin.

For further information, please contact:

Per Jansson, CEO
Tel: +46 709-17 47 46 or email:

Johanna Gräns, Ph.D., Regulatory Coordinator: Tel: +46 73-6509180 or email: 

About Us

Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see